News

GILD Stock Slips as CVS Health Excludes New HIV Drug Yeztugo

Gilead shares slip after CVS refused to add its new HIV drug, Yeztugo, while its Kite unit struck a $350 million deal with ...
TipRanks on MSN21h

Gilead Sciences Advances Lung Cancer Treatment with New Clinical Study

Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study. Gilead Sciences, in collaboration ...

CVS Health denies coverage for breakthrough HIV drug, committing 'clear violation' of ACA

CVS Health will not cover Gilead's Yeztugo, generic name lenacapavir (LEN), citing "clinical, financial, and regulatory ...